ClinicalTrials.gg

Program

fosmanogepix

Also written as “Fosmanogepix”, “APX001” and “Fosmanogepix IV infusion”.

Its studies are mostly in Mycoses · Candidemia · Invasive Fungal Infections, led by Basilea Pharmaceutica.

Furthest: phase 3, since Jun 7, 202213 company-led studies, 3 open or runningNext primary completion: Mar 9, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Basilea Pharmaceutica133 open or runningphase 3since Jun 7, 2022Nov 1, 2016Mar 9, 2027phase 1 · NCT07881224

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2016First studies: 2 phase 1 studies in MycosesFirst studyNCT02957929, NCT02956499
  2. Jul 19, 2018Phase 2 study in CandidemiaNCT03604705 · 21 enrolled · United States, Belgium, Germany and more
  3. Oct 30, 2019Phase 2 study in CandidemiaNCT04148287 · 9 enrolled · South Africa
  4. Nov 12, 2019Phase 1 study in MycosesNCT04166669 · 36 enrolled · Netherlands
  5. Jan 22, 2020Phase 2 study in Invasive Fungal InfectionsNCT04240886 · 21 enrolled · United States, Belgium, Germany and more
  6. Oct 1, 2020Phase 1 study in MycosesNCT04804059 · 10 enrolled · United Kingdom
  7. Jun 7, 2022Phase 3 study in CandidemiaNCT05421858 · 450 planned · United States, Argentina, Australia and more
  8. Aug 4, 2022Phase 1 study in Invasive Fungal InfectionsNCT05491733 · 18 enrolled · United States
  9. Oct 12, 2022Phase 1 study in Hepatic ImpairmentNCT05582187 · 28 enrolled · United States
  10. Mar 27, 2025Phase 3 study in MycosesNCT06925321 · 234 planned · United States, Australia, Austria and more
  11. Apr 24, 2025Phase 1 study in HealthyNCT06961708 · 54 enrolled · China
  12. Oct 12, 2026Phase 1 study in Healthy Adult ParticipantsNCT07881224 · 42 planned · Netherlands

Ahead

  1. Mar 9, 2027Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07881224
  2. Jan 30, 2028Primary completion: phase 3 study in CandidemiaNCT05421858
  3. Feb 2028Primary completion: phase 3 study in MycosesNCT06925321

TargetBeta

PIGW →read by rule
“An orally available small molecule inhibitor of the Gwt1 fungal enzyme ”NCIt, by rule
“GPI-anchored wall transfer protein 1 inhibitor”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07881224Healthy Adult Participants · Netherlands1RecruitingMar 9, 202742
NCT06961708Healthy · China1CompletedJul 15, 202554
NCT06925321Mycoses · United States, Australia, Austria and more3RecruitingFeb 2028234
NCT05582187Hepatic Impairment · United States1CompletedOct 16, 202528
NCT05491733Invasive Fungal Infections · United States1CompletedMay 13, 202118
NCT05421858Candidemia · United States, Argentina, Australia and more3RecruitingJan 30, 2028450
NCT04804059Mycoses · United Kingdom1CompletedSep 26, 201810
NCT04240886Invasive Fungal Infections · United States, Belgium, Germany and more2TerminatedMar 29, 202221
NCT04166669Mycoses · Netherlands1CompletedMar 3, 202036
NCT04148287Candidemia · South Africa2CompletedNov 30, 20209
NCT03604705Candidemia · United States, Belgium, Germany and more2CompletedMar 31, 202021
NCT02957929Mycoses · Netherlands1CompletedApr 20, 201746
NCT02956499Mycoses · Netherlands1CompletedJul 3, 2017200

How it is read

Names in the registry

  • “Fosmanogepix”, 4 entries
  • “APX001”, 4 entries
  • “Fosmanogepix IV infusion”, 1 entry
  • “Fosmanogepix oral tablet”, 1 entry
  • “Oral Fosmanogepix”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.